Two newer cholesterol drugs, when added to the strongest statins, can cut bad cholesterol by another half — helping high-risk patients get their levels down to what doctors recommend.

1

Pro

0

Against

Evidence from Studies

Supporting (1)

1

Community contributions welcome

1

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

Narrative Review

2025 Apr

The study looks at the same cholesterol drugs mentioned in the claim and finds they both significantly lower bad cholesterol on top of statins, helping high-risk patients reach healthy levels.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

Score: 1

DOI: 10.1016/j.pharmthera.2025.108812

Similar Assertions

Inclisiran is a type of medicine that helps lower bad cholesterol by turning down a protein in the liver. It works longer than some other cholesterol drugs, so you don’t need to take it as often.

1

0

80%

These cholesterol drugs, called PCSK9 inhibitors, probably help lower bad cholesterol in many types of patients — more than fake pills or other cholesterol medicines.

20

0

79%

These cholesterol drugs can cut bad cholesterol by half and help prevent heart attacks in people with heart disease, and they’re about as safe as a dummy shot—though some might get a little redness where they’re injected.

1

0

78%

Adding PCSK9 drugs to cholesterol-lowering statins can slash bad cholesterol by as much as 81% in people with high cholesterol.

68

33

77%

These special lab-made antibodies grab onto a protein in your blood that messes with cholesterol cleanup, so your body can get rid of bad cholesterol better and lower your chances of heart problems.

1

0

74%